NCT02084940

Long Acting GnRH Antagonist in PCOS Women Undergoing IVF

The Use of a Long Acting GnRH Antagonist (Degarelix) in Controlled Ovarian Hyperstimulation in PCOS Women at a Risk to Developing OHSS Undergoing IVF : a Pilot Study

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 20 (estimated)
• Sponsor: Bioroma · Academic / Other
• Sex: Female
• Age: 23 Years – 37 Years
• Healthy volunteers: Not accepted

Summary

PCOS is a common endocrinopathy affecting 5-10% of women in their reproductive age characterized by hyperandrogenism, chronic anovulation and polycystic ovaries. This syndrome is a serious problem in IVF since there is a high risk of developing ovarian hyperstimulation syndrome (OHSS) during ovarian stimulation with gonadotropins. The introduction of GnRH antagonist in IVF has reduced the incidence of severe OHSS, still maintaining a good ovarian response and pregnancy rate. Recently, a long acting GnRH antagonist, Degarelix, was introduced for prostatic cancer treatment. Furthermore a recent paper reported its use also for the induction of multiple follicular growth in a program of oocyte donation. The aim of this study is to evaluate the feasibility of GnRH antagonist depot use in a protocol of controlled ovarian hyperstimulation in PCOS women at risk of developing OHSS in IVF cycles.

Conditions

• Polycystic Ovarian Syndrome
• Ovarian Hyperstimulation Syndrome
• Invitro Fertilization

Interventions

Type	Name	Description
DRUG	GnRH antagonist depot Degarelix	Women receive 20 mg of Degarelix on the first day of menstrual cycle followed by a fixed dose of 225 IU of recombinant FSH on the second day until the day of ovulation triggering

Timeline

• Start date: 2014-03-01
• Primary completion: 2014-12-01
• Completion: 2015-02-01
• First posted: 2014-03-12
• Last updated: 2014-03-12

Locations

1 site across 1 country: Italy